Abstract:Background and Aims
Daratumumab is an anti-CD38 monoclonal antibody recently approved as a first-line therapy on top of standard therapy for the treatment of multiple myeloma and AL amyloidosis. The mechanism of action of Daratumumab is based on its ability to bind CD38, a transmembrane receptor expressed in particular by pathogenic plasma cells, inducing their death through multiple intra and extracellular signaling mechanisms and thus interrupting the production of monoclonal light chains a… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.